about
MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cellsNab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Beclin 1 and UVRAG confer protection from radiation-induced DNA damage and maintain centrosome stability in colorectal cancer cellsGenetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer.Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancers.Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations.Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinomaSurvival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use programRadiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues OncologuesSafety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer.Unusual iris metastasis from anal cancer: a case report.Aspirin and colorectal cancer: back to the future.Colonoscopy uptake for high-risk individuals with a family history of colorectal neoplasia: A multicenter, randomized trial of tailored counseling versus standard information.Management of esophageal adenocarcinoma.Future perspectives of circulating tumor DNA in colorectal cancer.Irreversible Electroporation for Locally Advanced Pancreatic Cancer: Where Do We Stand in 2017?Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.Anti program death-1/anti program death-ligand 1 in digestive cancers.Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.Cardiovascular events in chronic hepatitis C: prognostic value of liver stiffness evolution.High plasma levels of the pro-inflammatory cytokine IL-22 and the anti-inflammatory cytokines IL-10 and IL-1ra in acute pancreatitis.Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'Hyperkeratotic eczema of the nipple and areola associated with sorafenib treatment.Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.[Immunotherapy for colorectal cancer].Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease.Analysis of factors influencing molecular testing at diagnostic of colorectal cancer.Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.Association between clinicopathological characteristics and RAS mutation in colorectal cancer.Outcome of primary tumor in patients with synchronous stage IV colon or rectal cancer: so much the same yet so different.Clinical outcome of portal vein thrombosis in patients with digestive cancers: A large AGEO multicenter study.
P50
Q21133026-FB9F76C1-8BAC-4554-884F-4480BC8D26BEQ33425869-8D299258-9E4E-4D22-B29E-F25B8760B810Q33693309-6A0527B4-6AAF-4C92-917F-C638D9B90CA3Q33793750-81B565C9-1C8E-429B-B9D0-D41F86E63BC4Q34658903-90ABF1F8-A7BD-4CA6-86D0-78623020E9EAQ34683929-19732135-B7CA-4AC6-94E9-C6AAA491F0D0Q34985439-753084A7-CA5C-49C0-9678-DA836EA5F515Q35832569-287ACCBF-B61D-4B68-BD82-4AA724E82976Q36070573-A2EB755F-3835-49EC-BC45-586D4351BA4BQ36206880-B3F55D6B-8EC4-4E66-A56E-7E4C7027B0F7Q36977519-CA7CB76E-2020-43BC-ACB4-C10BD5E3FF56Q37092577-6DD94EE0-92DA-488A-8032-7D754CAC596EQ37626475-A810C7BB-2C4B-4761-9A15-6E05135BCEE8Q37726636-334D1A9B-1FA3-45D9-B73E-B07A198A0930Q37895778-6A19F84B-8B33-4A86-939E-0BDCC17B9EE1Q38685749-39823D3E-3EBC-4DA4-923A-8C80B8739FACQ39130366-5DB21E76-5A36-411D-8EE5-6587AF03F5B1Q40029238-2CFEF496-F141-4FAC-B69C-A9DA60DC3E41Q40202410-EFBB1302-76D0-4706-9E03-14188A4C8A4FQ40583605-F3B3DE09-3C41-4A71-AE06-D5EA5663104AQ40608710-323E00BD-C524-4FF9-B4F6-CDFC1AC6E9F8Q40850728-90F7F235-B362-4262-8594-65173C615404Q40860251-49B51E4D-8E16-424C-A6CC-9E68B15F233DQ41051631-188B55FD-B75F-4029-9154-6FB46B895FD0Q41732004-DE31F91A-6AAE-4F70-A0CC-4F6751826CD2Q42407052-C19E971D-690E-4AD9-8A36-61A821F4BF84Q42585933-C2485600-0494-4056-96CF-0DCE81873E1CQ42855352-211E7989-4105-40AB-8F14-028351F622AEQ43132795-FCCDE621-1044-4431-B37F-3137D0EF3FDAQ44247708-BFDBCB75-7C20-4873-A173-8546A932F8E7Q45376093-BA987FD3-FA36-48BA-80FB-F2DCD6D4197FQ45403194-58B9B31E-7FC7-4EF1-B9A1-82673905A9F0Q46050091-D9E50037-38F1-4605-A288-47194BBC123BQ46251612-F9E5BBB0-6E6B-4B51-8E82-27C2A4C2A411Q46728624-1E29B2E0-06FF-4862-A90C-4BA1829EFCCCQ47100522-34E1B0CA-15F5-48EC-B777-2C77123BE17AQ47423452-914CA482-F3E6-45E8-A0BF-53724EB77B2FQ48010330-BB6FE88B-13E0-4BC3-AC15-42029AF14D99Q48866055-7B2F484B-FB49-4738-96BF-149262467E22Q49567980-95A5E9D2-8A1E-478E-988A-FCA5DE9B38FB
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
David Tougeron
@ast
David Tougeron
@en
David Tougeron
@es
David Tougeron
@nl
type
label
David Tougeron
@ast
David Tougeron
@en
David Tougeron
@es
David Tougeron
@nl
prefLabel
David Tougeron
@ast
David Tougeron
@en
David Tougeron
@es
David Tougeron
@nl
P106
P21
P31
P496
0000-0002-8065-9635